Polymyalgia rheumatica medical therapy

Revision as of 02:28, 2 June 2014 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Polymyalgia Rheumatica Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyalgia rheumatica from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyalgia rheumatica medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyalgia rheumatica medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyalgia rheumatica medical therapy

CDC on Polymyalgia rheumatica medical therapy

Polymyalgia rheumatica medical therapy in the news

Blogs on Polymyalgia rheumatica medical therapy

Directions to Hospitals Treating Polymyalgia rheumatica

Risk calculators and risk factors for Polymyalgia rheumatica medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The mainstay of treatment of polymyalgia rheumatica (PMR) is low dose glucocorticoids, typically prednisone or prednisolone. The starting dose of the glucocorticoid treatment is 15-20 mg daily for 2 to 4 weeks after which the treatment should be slowly tapered. The average duration of the treatment with glucocorticoids is 1 to 2 years; nevertheless, longer corticosteroids regimens might be necessary among patients who experience relapse of the symptoms. Prophylaxis for osteoporosis with calcium and vitamin D should be started with the steroid therapy.

Medical Therapy

  • The mainstay of treatment of PMR is low dose glucocorticoids, typically prednisone or prednisolone:
    • The starting dose is 15-20 mg daily for 2 to 4 weeks
    • Gradually taper the steroid by decreasing the dose by 2.5 mg every 2 to 4 weeks
    • When the dose is 10 mg daily, decrease the dose by 1 mg every month
  • There should be close attention to the occurrence of symptoms of giant cell arteritis. Higher dose of glucocorticoids (40 mg daily) is indicated when patients with PMR develop giant cell arteritis
  • During the treatment, the subject's response to treatment should be monitored through:
    • Clinical symptoms
    • Measurement of ESR and CRP
  • Treatment lasts as long as needed; however, it normally takes patients several years to get off of the steroids. The symptoms may come back when the dosage is lowered. The average duration of the treatment with glucocorticoids is 1 to 2 years; nevertheless, longer corticosteroids regimens might be necessary among patients who experience relapse of the symptoms.

Other therapies

  • Etanercept may be safe and useful in relapsing PMR. It is modestly effective in PMR associated with giant cell arteritis than in isolated PMR. Trials are still in progress to determine the benefit and the differences in response.

References

  1. Caporali R, Cimmino MA, Ferraccioli G; et al. (2004). "Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial". Ann. Intern. Med. 141 (7): 493–500. PMID 15466766. Unknown parameter |month= ignored (help)
  2. Salvarani C, Macchioni P, Manzini C; et al. (2007). "Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial". Ann. Intern. Med. 146 (9): 631–9. PMID 17470831. Unknown parameter |month= ignored (help)

Template:WH Template:WS